Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Tivicay

Tivicay 10 mg film-coated tablets Tivicay 25 mg film-coated tablets Tivicay 50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9

HOS-129163 · Präparat HOS-096689

8 Darunavir/ritonavir Dolutegravir  No dose adjustment is necessary. AUC  22% Cmax  11% C24  38% (induction of UGT1A1 and CYP3A enzymes) Lopinavir/ritonavir Dolutegravir  No dose adjustment is necessary. AUC  4% Cmax  0% C24  6% Other Antiviral agents Daclatasvir Dolutegravir  Daclatasvir did not change dolutegravir plasma AUC  33% concentration to a clinically relevant extent. Cmax  29% Dolutegravir did not change daclatasvir plasma C  45% concentration. No dose adjustment is necessary. Daclatasvir  Other agents Potassium channel blocker Fampridine (also Fampridine  Co-administration of dolutegravir has the potential known as to cause seizures due to increased fampridine dalfampridine) plasma concentration via inhibition of OCT2 transporter; co-administration has not been studied. Fampridine co-administration with dolutegravir is contraindicated. Anticonvulsants Carbamazepine Dolutegravir  The recommended adult dose of dolutegravir is 50 AUC  49% mg twice daily when co-administered with Cmax  33% carbamazepine. In paediatric patients the weight- C  73% based once daily dose should be administered twice daily. Alternatives to carbamazepine should be used where possible for INI resistant patients. Oxcarbazepine Dolutegravir  The recommended adult dose of dolutegravir is 50 Phenytoin (Not studied, decrease mg twice daily when co-administered with these Phenobarbital expected due to induction of metabolic inducers. In paediatric patients the UGT1A1 and CYP3A weight-based once daily dose should be enzymes, a similar reduction administered twice daily. Alternative in exposure as observed combinations that do not include these metabolic with carbamazepine is inducers should be used where possible in INI- expected) resistant patients. Azole anti-fungal agents Ketoconazole Dolutegravir  No dose adjustment is necessary. Based on data Fluconazole (Not studied) from other CYP3A4 inhibitors, a marked increase Itraconazole is not expected. Posaconazole Voriconazole Herbal products St. John’s wort Dolutegravir  The recommended adult dose of dolutegravir is 50 (Not studied, decrease mg twice daily when co-administered with St. expected due to induction of John’s wort. In paediatric patients the weight- UGT1A1 and CYP3A based once daily dose should be administered enzymes, a similar reduction twice daily. Alternative combinations that do not in exposure as observed include St. John’s wort should be used where with carbamazepine is possible in INI-resistant patients. expected) Antacids and supplements

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) daclatasvir (HOS-119742) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) voriconazole (HOS-084524) itraconazole (HOS-084516) dalfampridine (HOS-124191) fluconazole (HOS-087945) darunavir (HOS-086181) oxcarbazepine (HOS-110224) ritonavir (HOS-084521) potassium (HOS-086929) phenytoin (HOS-084531) posaconazole (HOS-085622)